Search Within

Mrinal M Gounder

Formats
  1. Meeting Abstract (119)
  2. Journal Article (98)
  3. Review (4)
  4. Guidelines (2)
  5. Research Letter (2)
  6. Book Section (1)
  7. Correspondence (1)
  8. Editorial (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (229)
  2. Sarcoma Service (229)
  3. Solid Tumor Oncology Division (229)
  4. GSK Faculty (87)
  5. Hematologic Malignancies, Division of (85)
  6. Tow Center for Developmental Oncology (TCDO) (83)

More Groups

People
  1. William Tap (78)
  2. Mary Keohan (73)
  3. Sandra D'Angelo (73)
  4. Mark Dickson (70)
  5. Ping Chi (57)
  6. Li-Xuan Qin (52)

More People

Years
  1. 2025 (6)
  2. 2024 (17)
  3. 2023 (21)
  4. 2022 (36)
  5. 2021 (16)
  6. 2020 (25)

More Years

Publications
  1. Journal of Clinical Oncology (86)
  2. Annals of Oncology (24)
  3. Clinical Cancer Research (20)
  4. Cancer (7)
  5. The Oncologist (6)
  6. European Journal of Cancer (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (88)
  2. Oxford University Press (30)
  3. American Association for Cancer Research (29)
  4. Springer (14)
  5. Elsevier Inc. (11)
  6. Nature Publishing Group (10)

More Publishers

Results (229)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma
    Journal Article

    Kelly, C. M.; Qin, L. X.; Whiting, K. A.; Richards, A. L.; Avutu, V.; Chan, J. E.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Nirogacestat, a γ-secretase inhibitor for desmoid tumors
    Journal Article

    Gounder, M.; Ratan, R.; Alcindor, T.; Schöffski, P.; van der Graaf, W. T.; Wilky, B. A.; Riedel, R. F.; Lim, A.; Smith, L. M.; Moody, S.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • A first-in-human phase I study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas
    Journal Article

    Gounder, M. M.; Bauer, T. M.; Schwartz, G. K.; Weise, A. M.; LoRusso, P.; Kumar, P.; Tao, B.; Hong, Y.; Patel, P.; Lu, Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials
    Meeting Abstract

    Yamamoto, N.; Tolcher, A. W.; Hafez, N.; Lugowska, I.; Ramlau, R.; Gounder, M. M.; Geng, J.; Li, J.; Teufel, M.; Maerten, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas
    Meeting Abstract

    Gounder, M. M.; Schwartz, G. K.; Jones, R. L.; Chawla, S. P.; Chua-Alcala, V. S.; Stacchiotti, S.; Wagner, A. J.; Cote, G. M.; Maki, R. G.; Kosela-Paterczyk, H.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase I dose escalation study of a tegavivint (BC2059) a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumors
    Meeting Abstract

    Cranmer, L.; Razak, A. A.; Ratan, R.; Choy, E.; George, S.; Liebner, D.; Stenehjem, D.; Gounder, M.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Targeted sequencing of 2,138 bone and soft tissue sarcomas reveals commonly altered pathways, subtype-independent genetic clusters, and potential therapeutic targets
    Meeting Abstract

    Nacev, B. A.; Sanchez-Vega, F.; Smith, S.; Antonescu, C.; Rosenbaum, E.; Shi, H.; Tang, C.; Socci, N.; Rana, S.; Gularte-Merida, R.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)
    Meeting Abstract

    Kasper, B.; Ratan, R.; Alcindor, T.; Schoeffski, P.; van Der Graaf, W. T. A.; Wilky, B. A.; Riedel, R. F.; Lim, A.; Smith, L. M.; Moody, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT)
    Meeting Abstract

    Gounder, M. M.; Jones, R. L.; Chugh, R.; Agulnik, M.; Singh, A.; Van Tine, B. A.; Andelkovic, V.; Choy, E.; Lewin, J.; Ratan, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumours
    Meeting Abstract

    Schoeffski, P.; Yamamoto, N.; Bauer, T.; Patel, M.; Gounder, M. M.; Geng, J.; Sailer, R.; Jayadeva, G.; Lorusso, P.
    Annals of Oncology (2022)

    Fulltext@MSK | Save